Andrzej Nowojewski

Andrzej Nowojewski

Auto-generated profile, based on publicly available information

Andrzej Nowojewski

Clinical Pharmacology and Safety Sciences, Biopharmaceutical Research and Development, AstraZeneca, Cambridge, England, United Kingdom

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
SRSam Richardson
Sam Richardson
IAItziar Irurzun Arana
Itziar Irurzun Arana
ANAndrzej Nowojewski
Andrzej Nowojewski
DZDiansong Zhou
Diansong Zhou
JLJacob Leander
Jacob Leander
MGMegan Gibbs
Megan Gibbs
Background Population pharmacokinetic (PopPK) models are crucial for understanding drug behaviour across populations, yet traditional development is often labour-intensive and slow. This study demonstrates an automated, out-of-the-box approach for popPK model development, leveraging optimisation algorithms implemented using pyDarwin to efficiently handle a diverse range of extravascular drugs. Methods We proposed a generic model search space for drugs with extravascular administration and developed a penalty function to discourage over-parameterisation whilst ensuring plausible parameter values. Optimisation within the model search space was conducted using pyDarwin, employing Bayesian optimisation with a random forest surrogate combined with exhaustive local search. This approach was evaluated on one synthetic and four clinical datasets, with results compared to manually developed models. Results Here we show that the automated approach reliably identifies model structures comparable to manually developed expert models in less than 48 h on average (40-CPU, 40 GB environment) while evaluating fewer than 2.6% of the models in the search space. Ablation experiments demonstrate the importance of our penalty function in selecting plausible models, and the benefit of global search algorithms in avoiding local minima. Conclusions These results demonstrate that a single penalty function and model space can be used within the pyDarwin framework to automatically identify model structures for a diverse range of drugs. By reducing the configuration required at search setup, this approach simplifies the process, potentially making the technology more accessible to users. Adoption of automatic model search can accelerate popPK analysis, improve model quality, increase reproducibility, and reduce manual effort for modellers.

10 April 2024 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
ANAndrzej Nowojewski
Andrzej Nowojewski
EBErik Bark
Erik Bark
VSVivian H. Shih
Vivian H. Shih
RDRichard Dearden
Richard Dearden

4 February 2026 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
MKMarija Kekic
Marija Kekic
OSOleg Stepanov
Oleg Stepanov
WWWenjuan Wang
Wenjuan Wang
SRSam Richardson
Sam Richardson
DODamilola Olabode
Damilola Olabode
ANAndrzej Nowojewski
Andrzej Nowojewski
Covariate selection in population pharmacokinetics modeling is essential for understanding interindividual variability in drug response and optimizing dosing. Traditional stepwise covariate modeling is often time‐consuming, compared to the new machine learning alternatives. This study investigates the use of neural networks with stochastic gates for automated covariate selection, aiming to efficiently identify relevant covariates while penalizing excessive covariate inclusion. On various synthetic datasets, the approach demonstrated robustness in detecting important covariates, overcoming challenges such as high correlations, low covariate frequencies, high interindividual variability, and complex covariate dependencies. In real clinical data from a monalizumab study, the method successfully identified covariates that matched those found by experts. However, for tixagevimab/cilgavimab, it identified a superset of covariates, indicating a potential need for further pruning. This machine learning‐based method enhances the covariate preselection process in population pharmacokinetics model development, offering significant time savings and improving efficiency even under challenging scenarios.

28 October 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
ANAndrzej Nowojewski
Andrzej Nowojewski
AWAlex Wheal
Alex Wheal
WDWilliam Dott
William Dott
DRDario Ruscica
Dario Ruscica
SGSerban Ghiorghiu
Serban Ghiorghiu
BVBarbara Valastro
Barbara Valastro
Objectives To understand participant experience in the INTERLINK-1 clinical trial using the Study Participant Feedback Questionnaire (SPFQ), explore factors associated with participant experience and evaluate the implementation of the SPFQ. Design Phase 3, randomised, double-blind, placebo-controlled, multicentre trial. Setting 79 sites in 21 countries from October 2020 to October 2022. Participants 371 adults with recurrent/metastatic head and neck squamous cell carcinoma (39% aged >66 years, 69% White and 81% male). Primary outcome measures SPFQ administered at enrolment (SPFQ-A), during the trial (SPFQ-B) and at trial completion (SPFQ-C). Results A total of 223, 64 and 93 participants completed the SPFQ-A, SPFQ-B and SPFQ-C, respectively. Early termination of the INTERLINK-1 study limited the number of SPFQ-B and SPFQ-C responses. For all but one question, over 80% of participants selected positive responses, indicating positive experience with regards to enrolment (SPFQ-A), site (SPFQ-B) and overall trial (SPFQ-C). Individually, quality of life, continent and race were significantly associated with participant experience. Small numbers of negative and neutral responses enabled the construction of multiple ordinal regression models and were used to identify unbiased coefficients associated with patient experience. The models showed that males and participants in Asia reported worse experiences in questions regarding trial enrolment (p<0.05). Recent adverse events and higher Eastern Cooperative Oncology Group (ECOG) performance status were significantly negatively associated with trial site satisfaction (B1; OR 0.24, 95% CI 0.06 to 0.96, p<0.05) and site staff-related questions (B5; OR 0.18, 95% CI 0.04 to 0.93, p<0.05), respectively. Indications of acquiescence bias were found, possibly due to SPFQ question design. Conclusions Overall, participants reported positive experiences in the INTERLINK-1 study as evaluated by the SPFQ. Specific aspects of participant experience varied by sex, continent, recent adverse events and ECOG status. Further investigation is required to understand the causes of these findings to develop strategies for improved participant experience. Observations from this study will be used to inform future SPFQ implementation and develop strategies for better, more equitable trial experiences. Trial registration number ClinicalTrials.gov: NCT04590963.

24 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
RCRuoyi Cai
Ruoyi Cai
JGJoshua Gillard
Joshua Gillard
SYSherry Yang
Sherry Yang
LCLindsay Clegg
Lindsay Clegg
SGSamvel B. Gasparyan
Samvel B. Gasparyan
JOJack W. O’SUllivan
Jack W. O’SUllivan
Background: Clinical trials are essential for therapeutic development but increasingly face challenges due to imprecise inclusion criteria, leading to low event rates and the need for large sample sizes. This inefficiency makes modern trials costly and time-consuming. Despite the availability of extensive clinical, genomic, and biological data, current trial enrollment strategies do not fully leverage this information. Incorporating genomic information into trial design could enable risk-based participant enrichment by preferentially enrolling individuals with higher disease risk, thereby increasing event rates and improving trial efficiency. Methods: In this study, we developed an in silico framework for evaluating prognostic enrichment guided by polygenic risk scores (PRS) in clinical trial design using genomic and electronic health record data from large-scale biobanks. Naturally occurring protective genetic variants were used as analogs of therapeutic interventions, with variant carriers treated as ’treatment’ arms and non-carriers as ’control’ arms. We compared unenriched designs, in which carriers and non-carriers were drawn from the full population, against PRS-enriched designs in which both arms were restricted to participants in the upper 75%, 50%, or 25% of the PRS distribution, respectively. Across these four designs, we quantified disease prevalence, statistical power, sample size requirements, and time-to-event accrual. Results: We applied this approach to the UK Biobank using three model gene–disease pairs: the protective variant p.Arg46Leu in PCSK9 for coronary artery disease (CAD), p.Gln175His in ANGPTL7 for glaucoma, and p.Arg381Gln in IL23R for inflammatory bowel disease (IBD). Across all three disease contexts, PRS-enriched designs increased disease prevalence, improved empirical power, and accelerated event accrual relative to unenriched cohorts. At 80% power, restricting enrollment to the upper 25% of the PRS distribution reduced required per-arm sample sizes by approximately 60% for CAD-PCSK9 and 78% for IBD-IL23R. Consistent reductions in time-to-event were also observed across enriched strata, suggesting that PRS-enriched trials could achieve target event counts with both smaller sample sizes and shorter follow-up. However, for glaucoma-ANGPTL7, the most restrictive threshold did not yield additional gains over moderate enrichment, as reduced sample size attenuated the detectable difference between arms. These results highlight the need to balance enrichment for higher-risk participants against retaining a sufficient eligible population, and underscore that optimal PRS thresholds are disease-context dependent. Conclusions: These findings establish a generalizable, data-driven framework for prospectively evaluating PRS-guided prognostic enrichment prior to trial initiation. In general, PRS-guided study designs lead to improved empirical power, lower required sample sizes, and faster trials. As population-scale genomic data become increasingly available within healthcare systems and biobanks, this framework provides a scalable foundation for integrating genetic risk information into clinical trial design.

26 August 2026 in Journal of Patient Experience
Verified
Journal Article
Open access
RKRenate Kat
Renate Kat
WVWytske van der Veen
Wytske van der Veen
YGYoran H. Gerritsma
Yoran H. Gerritsma
MLMarika T. Leving
Marika T. Leving
WDWilliam Dott
William Dott
JKJanwillem Kocks
Janwillem Kocks
Understanding participant experience is crucial for improving participant satisfaction, retention, data quality, and clinical trial efficiency; particularly when incorporating digital patient solutions and virtual elements. CRESCENDO, an international phase-II chronic obstructive pulmonary disease (COPD) trial, incorporated daily at-home digital measurements, remote coached spirometry, and a virtual visit to evaluate feasibility and participant acceptance. This study explored participant experience in CRESCENDO through semi-structured interviews (n=21) and a Study Participant Feedback Questionnaire (SPFQ, n=81), conducted across Bulgaria, Canada, Poland, Spain, UK, and USA. Interview data were analysed thematically. Participants were generally satisfied and found digital and virtual elements user-friendly, although technical issues caused frustration. When functioning properly, participants considered remote and in-person spirometry coaching comparable. Nonetheless, participants preferred in-person visits due to positive interactions with trial staff, which increased satisfaction and feeling of appreciation. High concordance between interview and SPFQ data supported the validity of qualitative interviews for assessing participant experience. The study highlights the potential of digital elements and offers practical recommendations, like providing options for in-person and virtual visits, to enhance satisfaction and engagement. This qualitative sub-study was conducted within the CRESCENDO trial ( https://clinicaltrials .gov reference: NCT05492877).